Evidence map›Paper›PMID 33132652›Full record

ArticleWorld journal of gastroenterology2020

Real-world treatment attrition rates in advanced esophagogastric cancer.

Erica S Tsang, Howard J Lim, Daniel J Renouf, Janine M Davies, Jonathan M Loree, Sharlene Gill

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of gastroenterology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Erica S TsangDepartment of Medicine, BC Cancer, Vancouver V5Z 4E6, Canada.
Howard J LimDepartment of Medicine, BC Cancer, Vancouver V5Z 4E6, Canada.
Daniel J RenoufDepartment of Medicine, BC Cancer, Vancouver V5Z 4E6, Canada.
Janine M DaviesDepartment of Medicine, BC Cancer, Vancouver V5Z 4E6, Canada.
Jonathan M LoreeDepartment of Medicine, BC Cancer, Vancouver V5Z 4E6, Canada.
Sharlene GillDepartment of Medicine, BC Cancer, Vancouver V5Z 4E6, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundOver the last decade, multiple agents have demonstrated efficacy for advanced esophagogastric cancer (EGC). Despite the availability of later lines of therapy, there remains limited real-world data about the treatment attrition rates between lines of therapy.

aimTo characterize the use and attrition rates between lines of therapy for patients with advanced EGC.

methodsWe identified patients who received at least one cycle of chemotherapy for advanced EGC between July 1, 2017 and July 31, 2018 across six regional centers in British Columbia (BC), Canada. Clinicopathologic, treatment, and outcomes data were extracted.

resultsOf 245 patients who received at least one line of therapy, median age was 66 years (IQR 58.2-72.3) and 186 (76%) were male, Eastern Cooperative Oncology Group (ECOG) performance status 0/1 (80%), gastric

conclusionThe steep attrition rates between therapies highlight the unmet need for more efficacious early-line treatment options for patients with advanced EGC.

Indexed as

AdenocarcinomaEsophageal NeoplasmsStomach NeoplasmsAgedAntineoplastic Combined Chemotherapy ProtocolsBritish ColumbiaFemaleHumansKaplan-Meier EstimateMaleEsophagogastric cancerGastric cancerReal-world evidenceSystemic therapyTreatment attritionTreatment outcomes

Identifiers

PMID33132652
PMCPMC7584053

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.